What is the 13F Pro Quality Score for SMMT?

13F Pro ranks Summit Therapeutics Inc. (SMMT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SMMT's current score at https://13fpro.ai/research/SMMT (free sign-up required for the full ranking).

Which hedge funds own the most SMMT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SMMT include BAKER BROS. ADVISORS, FMR, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SMMT as soon as new 13F filings post.

Where does 13F Pro source SMMT data?

All Summit Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Summit Therapeutics Inc. files with the SEC under CIK 1599298. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SMMT in?

Summit Therapeutics Inc. (SMMT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SMMT research updated on 13F Pro?

SMMT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Summit Therapeutics Inc.(SMMT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1599298 SMMT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SMMT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Summit Therapeutics Inc. (SMMT), a Healthcare sector company. SMMT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Summit Therapeutics Inc. reports net income of $-189.4M, free cash flow of $-122.5M. Top institutional holders of SMMT by reported 13-F value include BAKER BROS. ADVISORS, FMR, BlackRock,, based on the most recent SEC filings. SMMT trades on the Nasdaq exchange and files with the SEC under CIK 1599298. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SMMT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Summit Therapeutics Inc. directly from SEC EDGAR. Summit Therapeutics Inc.'s 13F Pro composite quality score has ranged between 5 and 24 since 2021, currently 7.4 — a declining long-term trajectory across 9 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-189.4M

Free Cash Flow

Q1 2026

$-122.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY20 $860.0KFY22 $705.0KFY24 $0.00FY25 —

Net Income

-387.8% YoY

$-1.08BFY 2025

FY20 $-52.7MFY22 $-78.8MFY24 $-221.3MFY25 $-1.08B

Operating Income

—FY 2025

FY20 $-53.2MFY22 $-72.1MFY24 $-226.0MFY25 —

EPS (Diluted)

-364.5% YoY

$-1.44FY 2025

FY20 $-0.38FY22 $-0.41FY24 $-0.31FY25 $-1.44

Total Assets

+72.5% YoY

$751.2MFY 2025

FY20 $102.5MFY22 $664.2MFY24 $435.6MFY25 $751.2M

Op. Cash Flow

-127.2% YoY

$-322.9MFY 2025

FY20 $-48.1MFY22 $-41.6MFY24 $-142.1MFY25 $-322.9M

Metric	FY 2025	FY 2024	FY 2022	FY 2020
Revenue	—	$0.00 -100.0%	$705.0K -18.0%	$860.0K
Net Income	$-1.08B -387.8%	$-221.3M -180.9%	$-78.8M -49.5%	$-52.7M
Operating Income	—	$-226.0M -213.5%	$-72.1M -35.5%	$-53.2M
EPS (Diluted)	$-1.44 -364.5%	$-0.31 +24.4%	$-0.41 -7.9%	$-0.38
Total Assets	$751.2M +72.5%	$435.6M -34.4%	$664.2M +548.0%	$102.5M
Operating Cash Flow	$-322.9M -127.2%	$-142.1M -241.7%	$-41.6M +13.6%	$-48.1M

AI Insight: SMMT Financial Trends

Summit burned through $1.3B in equity over eight quarters while operating cash outflows accelerated to $122M in Q1 2026.

• Net losses spiked dramatically from $61M in Q4 2024 to $566M in Q2 2025 before moderating to $189M in Q1 2026.

• Operating cash outflows worsened steadily from $33M in Q2 2024 to $122M in Q1 2026.

• Equity declined from $438M in Q3 2024 to $192M in Q3 2025 before rebounding to $546M in Q1 2026.

⚠ Operating cash burn rate doubled from $61M in Q1 2025 to $122M in Q1 2026 over four quarters.

⚠ Company maintains zero debt but cash consumption patterns suggest potential future funding needs.

AI Insight: SMMT Ratio Trends

Summit Therapeutics shows deteriorating profitability with ROE worsening from -73.1% in Q1 2025 to -138.8% in Q1 2026.

• ROE declined sharply from -73.1% in Q1 2025 to -138.8% in Q1 2026, indicating worsening losses relative to equity.

• ROA deteriorated from -44.8% in Q3 2024 to -65.6% in Q1 2025 before data became unavailable.

• ROIC showed negative -53.3% in Q3 2024 and worsened to -67.5% in Q4 2024 before gaps appeared.

⚠ Extensive data gaps across all profitability metrics in recent quarters limit visibility into operational trends.

⚠ Consistent negative returns across all available periods suggest ongoing cash burn without revenue generation typical of biotech development.

Get alerted when SMMT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Summit Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SMMT

BAKER BROS. ADVISORS LP
$690.0M36,391,063 sh
FMR LLC
$205.8M10,853,199 sh
BlackRock, Inc.
$183.0M9,653,758 sh
STATE STREET CORP
$133.3M7,028,160 sh
VANGUARD CAPITAL MANAGEMENT LLC
$108.3M5,711,802 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$99.2M5,233,252 sh
UBS Group AG
$69.8M3,680,315 sh
GEODE CAPITAL MANAGEMENT, LLC
$62.9M3,315,854 sh
D. E. Shaw & Co., Inc.
$42.5M2,242,229 sh
MORGAN STANLEY
$31.3M1,650,591 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$690.0M	36,391,063
FMR LLC	$205.8M	10,853,199
BlackRock, Inc.	$183.0M	9,653,758
STATE STREET CORP	$133.3M	7,028,160
VANGUARD CAPITAL MANAGEMENT LLC	$108.3M	5,711,802
VANGUARD PORTFOLIO MANAGEMENT LLC	$99.2M	5,233,252
UBS Group AG	$69.8M	3,680,315
GEODE CAPITAL MANAGEMENT, LLC	$62.9M	3,315,854
D. E. Shaw & Co., Inc.	$42.5M	2,242,229
MORGAN STANLEY	$31.3M	1,650,591

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SMMT on your watchlist

Track score changes the day Summit Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SMMT a good stock to buy?

13F Pro's AI-powered analysis of Summit Therapeutics Inc. (SMMT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SMMT are available on the SMMT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SMMT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SMMT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Summit Therapeutics Inc.'s investment landscape.